CIK 0001590877
- Non-accelerated filer
- Smaller reporting company
REGENXBIO Inc.
Sign in to watch- Ticker
- RGNX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 471851754
- Phone
- +1 240-552-8181
- Business address
- 9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
- Former names
- ReGenX Biosciences, LLC
- 4 Exercise or conversion Chief Financial Officer acquired 120,000 shares (option exercise)
- 4 Open-market sale SVP, Product Development & CTO sold 43,832 shares at $50.08 ($2,195,107)
- 4 Exercise or conversion President and CEO acquired 45,000 shares (option exercise)
- 4 Open-market sale President and CEO sold 15,000 shares at an average $43.85 ($657,698)
- 4 Grant or award SVP, General Counsel acquired 337 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market sale SVP, General Counsel sold 5,000 shares at an average $47.54 ($237,698)
- 4 Open-market sale Chief Financial Officer sold 7,500 shares at an average $46.35 ($347,650)
- 4 Open-market sale President and CEO sold 15,000 shares at an average $46.73 ($700,927)
- 4 Open-market sale Chief Medical Officer sold 20,414 shares at an average $60.13 ($1,227,412)
- 4 Open-market sale President and CEO sold 20,000 shares at an average $60.40 ($1,208,087)
- 4 Exercise or conversion Chief Scientific Officer acquired 1,500 shares (option exercise)
- 4 Open-market sale Director sold 12,784 shares at $65.00 ($830,960)
- 4 Open-market sale Director sold 20,507 shares at an average $65.03 ($1,333,519)
- 4 Open-market sale President and CEO sold 20,000 shares at an average $64.17 ($1,283,355)
- 4 Open-market sale President and CEO sold 15,000 shares at an average $61.44 ($921,660)
- 4 Open-market sale Director sold 33,292 shares at an average $60.44 ($2,012,209)
Page 13 of 22 · 435 filings